Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pharvaris N.V.PHVS · Entity 4374 | Director · Chief Executive Officer | September 17, 2026 | September 21, 2026 |
| Sio Gene Therapies Inc.SIOX · Entity 130622 | Director | April 15, 2021 | April 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pharvaris N.V.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Schoodic Management BV | 650,000 |
Reported balance
After 2026-09-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-09-17 · Exercise / conversion · Disposed 300,000 · Balance 650,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Schoodic Management BV | 650,000 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 650,000 F1: Schoodif Management BV, an entity controlled by Mr. Modig |
Filing footnotes · ownership attribution and instrument terms
F1: Schoodif Management BV, an entity controlled by Mr. Modig
Sio Gene Therapies Inc.
Report date April 15, 2021 · Filed April 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2031-04-14 | Direct | 42,000 |
Reported balance
After 2021-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-15 · Grant · Acquired 42,000 · Balance 42,000 F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 19:10 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 300,000 | $35.00 | $10,500,000.00 |
DisclosureSEC source: 0001193125-26-396565 · ownership.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Schoodic Management BV Disclosed balance after: 650,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 18:15 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 2,291 | $39.40 | $90,275.94 |
DisclosureSEC source: 0001193125-26-391713 · ownership.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,334 F1 · kind: The shares were acquired upon vesting of restricted stock units and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.69 to $40.39. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 15:49 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 2,292 | $34.77 | $79,685.73 |
DisclosureSEC source: 0001193125-26-354965 · ownership.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,625 F1 · kind: The shares were acquired upon vesting of restricted stock units and sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 13, 2026 Filed Jul 15, 2026 17:08 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 2,292 | $34.97 | $80,154.45 |
DisclosureSEC source: 0001193125-26-304445 · ownership.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,917 F1 · kind: This is a scheduled sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $34.68 to $35.11. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:51 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 100 | $31.46 | $3,146.00 |
DisclosureSEC source: 0001193125-26-274440 · ownership.xml · nonDerivative · entry 2 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,209 F1 · kind: This is a scheduled sale from 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:51 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 2,191 | $31.05 | $68,027.04 |
DisclosureSEC source: 0001193125-26-274440 · ownership.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,309 F1 · kind: This is a scheduled sale from 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.43 to $31.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:33 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 2,292 | $29.22 | $66,976.82 |
DisclosureSEC source: 0001193125-26-232892 · ownership.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,500 F1 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $29.47 - $30.40. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 19:00 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 2,292 | $28.60 | $65,558.53 |
DisclosureSEC source: 0001193125-26-163713 · ownership.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,792 F1 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $28.32 to $28.82. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 17:42 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 200 | $28.42 | $5,683.00 |
DisclosureSEC source: 0001193125-26-150954 · ownership.xml · nonDerivative · entry 2 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,084 F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $28.32 to $28.51. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 17:42 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 23,133 | $27.74 | $641,598.38 |
DisclosureSEC source: 0001193125-26-150954 · ownership.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,284 F1 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $27.31 to $28.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:54 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001636050-21-000047 · wf-form4_161886566617176.xml · derivative · entry 1 Modig Berndt · CIK 0001643072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2031-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 01:10 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001209191-20-025023 · doc4.xml · derivative · entry 1 Modig Berndt · CIK 0001643072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Shares · 17,500 shares Expires 2030-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 01:15 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 255,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025190 · doc4.xml · derivative · entry 1 Modig Berndt · CIK 0001643072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:33 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-18-020367 · doc4.xml · derivative · entry 1 Modig Berndt · CIK 0001643072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: 100% of this option will vest on March 15, 2019, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 13:39 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | Exercise / conversionStock Option (right to buy) · Derivative | 77,914 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001104659-18-000368 · a4.xml · derivative · entry 2 Modig Berndt · CIK 0001643072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,086 Underlying: Common Stock · 77,914 shares Expires 2025-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests over a period of three years, with one third of the common shares underlying the option having vested on March 18, 2016 and the remainder vesting in eight equal quarterly installments thereafter. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 13:39 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | Exercise / conversionCommon Stock | 77,914 | $0.90 | $70,122.60 |
DisclosureSEC source: 0001104659-18-000368 · a4.xml · nonDerivative · entry 1 Modig Berndt · CIK 0001643072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2017 Filed May 3, 2017 01:04 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $24.24 | $0.00 |
DisclosureSEC source: 0001209191-17-029472 · doc4.xml · derivative · entry 1 Modig Berndt · CIK 0001643072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Shares · 27,000 shares Expires 2027-04-28 F1 · derivative.exercise_date: 100% of this option will vest one year after the date of grant. The option allows for early exercise, subject to the issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F2 · balance_after: Includes only options with the same termination date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.